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CLINICAL SCIENCE
Self-Reported Decline in Everyday Function, Cognitive
Symptoms, and Cognitive Function in People
With HIV
Rosanna Laverick, MRes,* Lewis Haddow, PhD, MBChB,* Marina Daskalopoulou, MSc,*
Fiona Lampe, PhD,* Richard Gilson, MD, MBBS,* Andrew Speakman, PhD,* Andrea Antinori, MD,†
Tina Bruun, MD,‡ Anna Vassilenko, MD,§ Simon Collins,ǁ and Alison Rodger, PhD, MBChB,*
for the Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group
Background: We determined factors associated with self-reported
decline in activities of daily living (ADLs) and symptoms of
cognitive impairment in HIV positive adults in 5 European clinics.
Methods: HIV+ adults underwent computerized and pen-and-paper
neuropsychological tests and questionnaires of cognitive symptoms
and ADLs. We considered cognitive function in 5 domains,
psychosocial factors, and clinical parameters as potentially associ-
ated with symptoms. Separate regression analyses were used to
determine factors associated with a decline in ADL (deﬁned as self-
reported decline affecting $2 ADLs and attributed to cognitive
difﬁculties) and self-reported frequency of symptoms of cognitive
impairment. We also estimated the diagnostic accuracy of both
questionnaires as tests for cognitive impairment.
Results: Four hundred forty-eight patients completed the assessments
[mean age 45.8 years, 84% male, 87% white, median CD4 count
550 cells/mm3, median time since HIV diagnosis 9.9 years, 81%
virologically suppressed (HIV-1 plasma RNA ,50 copies/mL)].
Ninety-six (21.4%) reported decline in ADLs and attributed this to
cognitive difﬁculties. Self-reported decline in ADLs and increased
symptoms of cognitive impairment were both associated with worse
performance on some cognitive tests. There were also strong associ-
ations with ﬁnancial difﬁculties, depressive and anxiety symptoms,
unemployment, and longer time since HIV diagnosis. Both question-
naires performed poorly as diagnostic tests for cognitive impairment.
Conclusions: Patients’ own assessments of everyday function and
symptoms were associated with objectively measured cognitive
function. However, there were strong associations with other psycho-
social issues including mood and anxiety disorders and socioeconomic
hardship. This should be considered when assessing HIV-associated
cognitive impairment in clinical care or research studies.
Key words: HIV, HIV dementia, neuropsychological assessment,
MCI (mild cognitive impairment), activities of daily living
(J Acquir Immune Deﬁc Syndr 2017;76:e74–e83)
INTRODUCTION
Several studies have reported high prevalence of cogni-
tive impairment in HIV+ patients, with the highest estimates
exceeding 50%.1,2 However, a large proportion of individuals
scoring below speciﬁed thresholds on cognitive testing and
meeting the criteria for HIV-associated neurocognitive disorder
(HAND) have no interference with everyday functioning and
are categorized as having asymptomatic neurocognitive impair-
ment (ANI) by the Frascati criteria.3 Others have used
participant self-report methods such as the modiﬁed Lawton
& Brody Instrumental Activities of Daily Living Scale
(IADLS) to discriminate mild neurocognitive disorder (MND)
from ANI.2,4–6 Deterioration, if deﬁned as a change from ANI
to MND, is based solely on the assessment of difﬁculties with
activities of daily living (ADL), therefore discerning this
change is highly important. Functional decline and cognitive
symptoms may also be the main driver of patients coming to
clinicians’ attention in clinical settings.
Some studies have suggested limited validity of patient
self-report with commonly used questionnaires when used to
predict objectively measured cognitive function.7–10 But even if
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symptoms are only weakly correlated with cognitive impair-
ment, they are in some sense highly important to the patient.
There are likely to be psychological and other factors underlying
reported symptoms and understanding these factors may steer
the clinician away from investigations such as brain imaging and
lumbar puncture and toward the patients’ more pertinent needs.
In this analysis, we aimed to measure the strength of association
between self-reported decline in ADL, self-reported symptoms
of cognitive impairment, and objectively measured cognitive
function. We then sought to determine which other factors were
associated with these symptoms of cognitive difﬁculties.
METHODS
Participants
The Cognitive Impairment in People with HIV in the
European Region (CIPHER) study is a European study of
cognitive function in HIV+ adult outpatients (2 clinics in
London, United Kingdom; one clinic in each of Copenhagen,
Denmark; Minsk, Belarus; Rome, Italy). We recently reported,
along with detailed psychosocial and clinical cofactors, a 35%
prevalence of cognitive impairment, of whom more than half
met Frascati criteria for ANI and a quarter had confounding
conditions, with the remaining 6% having MND or HAD.11
Participants were recruited opportunistically from May 2011 to
January 2013 regardless of symptoms, treatment, and comorbid-
ities. All questionnaires were self-completed in a written format
by the participant in the local language, and participants had to
be sufﬁciently cognitively intact to complete study procedures.
Ethical Approval
The study was approved by the UK National Research
Ethics Service—London Hampstead Committee (11/LO/
0077), De Videnskabsetiske Komiteér for Region Hovedsta-
den (H-4-2011-105), the Ethics Committee of the Minsk
Municipal Infectious Diseases Hospital (04/2011), and the
Comitato Etico of Istituto Nazionale Malattie Infettive (66/
2011). All study participants gave written informed consent
before commencing the study.
Assessment of Symptoms and Self-
Reported Function
Declining function in ADLs was measured using the
Modiﬁed Lawton & Brody IADLS, which required participants
to indicate their current and, retrospectively, their “best ever”
level of function on 16 activities, according to a 3- or 4-point
scale (see Supplemental Digital Content 1, http://links.lww.
com/QAI/B55). Where their current level was worse than their
best ever level, participants recorded the perceived cause as
“primarily cognitive problems,” “primarily physical problems,”
or “equally cognitive and physical problems.” The question-
naire has been used in large published studies of HAND.2,12,13
Symptoms of cognitive impairment were elicited using 4
questions from the Medical Outcomes Study in HIV (MOS-
HIV)14 (see Supplemental Digital Content 2, http://links.lww.
com/QAI/B55). Participants were asked to indicate how much of
the time in the past 4 weeks they had experienced difﬁculty
reasoning and solving problems, forgetfulness, trouble keeping
their attention, and difﬁculty in concentration. Possible responses
were scored: 0, none of the time; 1, a little bit of the time; 2,
some of the time; 3, a good bit of the time; 4, most of the time; 5,
all of the time. Adding the 4 responses gave a total score of 0–20.
Participants completed the 9-item Patient Health Ques-
tionnaire (PHQ-9) for depression15 and the 7-item General-
ized Anxiety Disorder (GAD-7) questionnaire for anxiety.16
These questionnaires elicit symptom frequency in the past 2
weeks: 0, not at all; 1, several days; 2, more than half the
days; 3, nearly every day. PHQ-9 scores ranged from 0 to 27
and were graded: 0–4, none/minimal; 5–9, mild; 10–14,
moderate; 15–19, moderate-severe; 20–27, severe. GAD-7
scores ranged from 0 to 21 and were graded: 0–4, none/
minimal; 5–9, mild; 10–14, moderate; 15–21, severe.
Cognitive Testing
The study used Cogstate, software adapted from
standard neuropsychological (NP) tasks for assessment of
multiple cognitive domains (http://cogstate.com/academic-
2/measurement-of-cognition)17–19 and 2 pen-and-paper NP tests.
Cogstate is mainly nonlanguage based, and the stimuli vary
randomly between assessments, reducing the inﬂuence of
cultural, educational, and practice effects. Several studies have
used Cogstate in HIV+ patients in anglophone countries,20–26
with work demonstrating good construct validity and correlation
with traditional pen-and-paper NP batteries,21–23 and the method
has been used in children and adults in diverse settings in Africa
and Asia27–29 (although not in all countries where CIPHER was
based). Ten tests were organized into 5 domains: psychomotor
speed (Detection and Identiﬁcation); verbal memory (Shopping
List learning and recall); executive function (Groton Maze
learning and recall; these tests also assess visuospatial learning
and memory); working memory (One-Back speed and accu-
racy); verbal ﬂuency (2 pen-and-paper tests: Controlled Oral
Word Association Test and Category Fluency Test). Testing
included a full practice run (not scored) on the same day as the
main assessment.30
Each cognitive test was converted to an age-, sex-, and
education-standardized Z-score using normative mean values
and SD. Normative data for the computerized tests were
provided by Cogstate from Europe, United States of America,
South East Asia, and Australia/New Zealand, frequency-
matched for age (18–34, 35–50, and 51+ years; minimum cell
size n = 145), sex (157 female, 377 male), and education
(university/further education, n = 243, or secondary school, n =
291). The normative population excluded individuals with
clinical or functional impediments to test performance, and
subsets of these data had been used previously to measure
cognitive function in HIV+ adults.20–22,24,26 Published norms
were used for the Controlled Oral Word Association Test and
Category Fluency Test.31,32 A continuous measure of neuro-
cognitive function was calculated from the mean of all 5
neuropsychological domain Z scores (NPZ-5).
Other Data Collection
Drug and alcohol use, educational attainment, and
socioeconomic information were obtained from self-report.
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Medical and psychiatric histories were obtained from both
patient report and clinical notes. Clinical information included
current HIV viral load, CD4 count, antiretroviral therapy
history, HIV-related complications, laboratory markers, and
neurological and psychiatric comorbidities. Hepatitis C virus
(HCV) status was deﬁned as the most recent HCV RNA assay
or the most recent antibody result in the absence of an RNA
result. Participants with any of a prespeciﬁed list of comorbid
conditions (published as an appendix to the original criteria3)
—including depressive disorders, historical traumatic brain
injury, developmental disabilities, alcohol and substance use
disorders, certain HIV-related and non–HIV-related neuro-
logic conditions, and systemic disease likely to affect
cognition—were noted. We adopted the nomenclature used
by the CHARTER group, where contributing conditions were
those with potential for mild cognitive impairment, whereas
confounding conditions were those likely to have a substantial
effect on cognitive function.2
Statistical Analyses
The ﬁrst outcome measure was deﬁned, using the
IADLS, as self-reported decline in 2 or more ADLs of the
possible 16 (designated “functionally dependent” by Ober-
meit et al7) and attribution to cognitive problems by the
participant. To harmonize our results with Obermeit and
others, we included ADLs that had been omitted in our
previous analysis,11 namely planning social activities, read-
ing/watching television, and childcare. The associations of
age, sex, ethnic group (white versus other ethnic groups),
study site, educational attainment (as ordered categories of
primary, secondary, and higher education), employment
status (as a categorical variable of in employment, unable to
work, or unemployed for other reasons), cognitive function
(as a continuous variable by domain and as a mean score),
clinical data, and psychosocial variables were estimated by
odds ratios (ORs) and 95% conﬁdence intervals (CIs). All
cognitive function scores and factors found to be at least
moderately associated with the outcome (at a threshold of
P , 0.1) were included in separate logistic regression models
with adjustment for demographic variables (age, sex, ethnic
group, study site, and education). Education, site, and
ethnicity have been identiﬁed as factors associated with
cognitive test scores in an earlier analysis of the same study
sample.11
The second outcome measure was symptom score from
the MOS-HIV questionnaire in 5 ordered categories. The base
category was deﬁned as asymptomatic (0 points on the
questionnaire) and subsequent categories corresponded to 4
quartiles of the remaining values. Ordered logistic regression
was used to calculate ORs and CIs for each factor in the same
way as the ADL decline outcome measure. The ordered
logistic model assumes the same effect size for each unit
increase in the outcome. Multivariable regression models
were also constructed for factors with P , 0.1 in the bivariate
analyses, adjusted for demographic variables, in the same way
as the ﬁrst outcome measure.
Finally, we assessed the possible application of the
IADLS and MOS-HIV symptom questionnaires as diagnostic
or screening tools for cognitive impairment. Two reference
standards were used, deﬁned as low performance in 2 or more
cognitive domains to a level of Z #21 (mild cognitive
impairment) or Z #22 (severe cognitive impairment).
Receiver operator curves were generated from sensitivity
and speciﬁcity statistics for all possible thresholds on each
scale (number of ADLs of difﬁculty when attributed by the
patient to cognitive problems and MOS-HIV cognitive
symptom score). Test accuracy statistics [positive and
negative likelihood ratios (LRs) and diagnostic odds ratios
(DORs)] were calculated.
RESULTS
Study Population
Of 486 patients recruited, 448 (92%) completed all
cognitive assessments [London 292 (65%); Rome 90 (20%);
TABLE 1. Characteristics of HIV-Positive Study Participants
(N = 448)
n/N %
Mean (SD) or
Median (IQR)
Age, yr 45.8 (9.6)
Male sex 378/448 84.4
MSM 306/429 71.3
White ethnicity 389/440 88.4
Migrant* 118/429 27.5
Can always afford basic needs 247/429 57.6
Educational attainment
University or other higher education 249/429 58.0
Secondary school 101/429 23.5
Primary school 79/429 18.4
Employment status
In employment 255/421 60.6
Unable to work 43/421 10.2
Other reasons for unemployment 123/421 29.2
Recent psychoactive drug use† 132/448 29.5
Any previous IDU 40/448 8.9
Problem drinking‡ 167/428 39.0
Major depressive symptoms§ 111/436 25.5
Major anxiety symptoms§ 87/435 20.0
Latest CD4 count, cells/mL 550 (410–750)
Nadir CD4 count, cells/mL 290 (160–500)
Years since positive HIV result 9.9 (4.8–16.2)
On ART 400/448 89.3
HIV RNA ,50 copies/mL 363/448 81.0
HCV║ 64/441 14.5
*Deﬁned as those not born in the country of assessment.
†Deﬁned as self-reported consumption of amphetamines (including methamphet-
amine), cocaine, cannabis, and opiates for nonmedicinal use, ketamine, gamma-
hydroxybutyrate, gamma-butyrolactone, psychedelics, or mephedrone in the past
3 months.
‡Deﬁned by the modiﬁed (two-question) AUDIT-C questionnaire: a positive score
was $4 points for men or $3 points for women.
§Deﬁned as $10 points on the PHQ-9 (depression) or GAD-7 (anxiety) scale.
║Deﬁned as the most recent HCV RNA assay or the most recent antibody result in
the absence an RNA result.
ART, antiretroviral therapy; IDU, intravenous drug use; IQR, interquartile range;
MSM, men who have sex with men.
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Copenhagen 42 (9.4%); Minsk 24 (5.4%)], 15 participants
only completed the practice assessment, and 23 completed
fewer than 5 cognitive domains. The sample was 87% white,
84% male, mean 45.8 years of age (SD 9.6), 89% on
antiretroviral therapy, and 81% with viral load ,50 copies/
mL. Participant characteristics are shown in Table 1 (break-
down by study site has already been published11).
Factors Associated With Self-Reported
Decline in ADL
Self-reported functional decline in 2 or more ADLs was
present in 138 participants (30.8%). This was attributed to
cognitive problems, with or without physical problems, by 96
(69.6% of those reporting decline). The most frequent
difﬁculties were socializing, work, and housekeeping, affect-
ing 55%–72% of functionally impaired patients and 5%–15%
of patients with fewer than 2 areas of difﬁculty (Fig. 1).
Information on speciﬁc ADLs was not available for partic-
ipants at the Italian site (n = 90), and 134 of the remainder
(37.4%) left the childcare item blank or responded “I do not
have children”; these individuals were assumed not to have
declined in this activity.
Several factors were associated with self-reported decline
in ADLs attributed to cognitive impairment (Table 2). In models
adjusted for age, sex, ethnic group, education, and study site,
a decline in ADLs was associated with speed/reaction time
[adjusted odds ratio (aOR) 0.68 per Z +1, 95% CI: 0.55 to 0.83]
and attention/working memory (aOR 0.57 per Z +1, 95% CI:
0.42 to 0.78). Other associated factors were as follows: ability to
afford basic needs most of the time (aOR 2.71, 95% CI: 1.52 to
4.80) or some of the time (aOR 4.44, 95% CI: 2.01 to 9.81)
compared with those who were always able to afford basic
needs; being unable to work (aOR 3.99, 95% CI: 1.94 to 8.22)
or unemployed for other reasons (aOR 2.21, 95% CI: 1.26 to
3.86) compared with those in employment; depressive symp-
toms (aOR 2.06 per grade on the PHQ-9 scale, 95% CI: 1.66 to
2.55); anxiety symptoms (aOR 2.20 per grade on the GAD-7
scale, 95% CI: 1.69 to 2.88); and HIV diagnosis 5–10 years ago
(aOR 3.18, 95% CI: 1.42 to 7.13) or $10 years ago (aOR 3.62,
95% CI: 1.62 to 8.09).
To explore the interdependence of the effects of mood,
cognition, and functional abilities, we analyzed whether
adjusting for relevant cognitive domains would change the
association between PHQ-9 grade and self-reported decline in
ADLs. The effect after including the speed domain was an
aOR of 1.95 (95% CI: 1.58 to 2.41), and the effect after
including attention and working memory was an aOR of 1.96
(95% CI: 1.59 to 2.42), both being similar to the results of the
simpler model. In addition, there was no evidence of an
interaction between depression and functional decline in their
effects on the speed domain (P = 0.37) or on the attention/
working memory domain (P = 0.84).
Factors Associated With Self-Reported
Symptoms of Cognitive Impairment
MOS-HIV scores were available for 440 participants,
with a median score of 4 (IQR 1–8). Numbers in each of the 5
ordered categories were as follows: 86 asymptomatic (0
points, 19.6%); 115 with grade 1 (1–3 points, 26.1%); 70 with
grade 2 (4–5 points, 15.9%); 85 with grade 3 (6–9 points,
19.3%); and 84 with grade 4 (10–20 points, 19.1%). In
multivariable ordered logistic regression models adjusted for
age, sex, ethnic group, education, and study site (Table 3),
increasing grade of symptom frequency was associated with
impairment of speed/reaction time (aOR 0.68 per +1 in Z
score, 95% CI: 0.58 to 0.80), attention/working memory
(aOR 0.60, 95% CI: 0.47 to 0.77), verbal memory (aOR 0.87,
95% CI: 0.77 to 0.98), and verbal ﬂuency (aOR 0.84, 95% CI:
0.71 to 1.00). Other associated factors were as follows: being
educated to only primary school level compared with
FIGURE 1. Proportion of patients
reporting decline in specific ADL
who were functionally impaired (n =
117) or not functionally impaired
(n = 241).
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TABLE 2. Factors Associated With Self-Reported Decline in ADL Attributed to Cognitive Impairment
Unadjusted OR (95% CI) P aOR (95% CI)* P
Age per +10 yrs 1.09 (0.86 to 1.38) 0.49 0.96 (0.73 to 1.26) 0.78
Gender and sexual orientation
MSM 1 1
Other men 1.25 (0.70 to 2.26) 1.66 (0.75 to 3.71)
Women 0.52 (0.24 to 1.09) 0.13 0.93 (0.40 to 2.16) 0.39
Ethnic group
White 1 1
Other or not known 2.11 (1.17 to 3.83) 0.014 1.21 (0.59 to 2.48) 0.60
Education‡
University/higher 1 1
Secondary 0.80 (0.44 to 1.47) 0.92 (0.48 to 1.78)
Primary only 1.53 (0.85 to 2.73) 0.27 1.41 (0.76 to 2.62) 0.35
Employment status
In employment 1 1
Unable to work 5.47 (2.72 to 10.98) 3.99 (1.94 to 8.22)
Other 2.36 (1.43 to 3.92) ,0.0001 2.21 (1.26 to 3.86) 0.0003
Site
London 1 1
Rome 0.36 (0.18 to 0.72) 0.33 (0.15 to 0.71)
Copenhagen 0.20 (0.06 to 0.67) 0.23 (0.07 to 0.76)
Minsk 0.11 (0.02 to 0.85) 0.0004 0.11 (0.01 to 0.92) 0.002
Mean Z (all domains) per +1 SD 0.76 (0.61 to 0.96) 0.019 0.70 (0.54 to 0.91) 0.009
Speed Z per +1 SD 0.75 (0.63 to 0.90) 0.002 0.68 (0.55 to 0.83) ,0.0005
Attention/working memory Z per +1 SD 0.68 (0.51 to 0.90) 0.006 0.57 (0.42 to 0.78) ,0.0005
Executive function Z per +1 SD 0.96 (0.88 to 1.05) 0.41 0.97 (0.88 to 1.07) 0.56
Verbal memory Z per +1 SD 0.92 (0.81 to 1.06) 0.26 0.90 (0.77 to 1.06) 0.22
Verbal ﬂuency Z per +1 SD 0.87 (0.70 to 1.08) 0.21 0.87 (0.69 to 1.10) 0.24
Confounding comorbid condition†
No 1 1
Yes 1.86 (1.09 to 0.51) 0.024 1.61 (0.91 to 2.84) 0.10
Contributing comorbid condition†
No 1
Yes 1.57 (0.86 to 2.87) 0.14
Can afford basic needs‡
Always 1 1
Most of the time 2.64 (1.53 to 4.56) 2.71 (1.52 to 4.80)
Some of the time 4.05 (1.93 to 8.51) 4.44 (2.01 to 9.81)
No 2.47 (1.01 to 6.03) 0.0002 2.40 (0.94 to 6.11) 0.0003
Recreational psychoactive drugs in past 3 mo
No 1
Yes 1.42 (0.88 to 2.29) 0.15
Problem drinking§
No 1
Yes 1.41 (0.88 to 2.25) 0.15
Depressive symptoms per grade‡║ 2.11 (1.73 to 2.57) ,0.0005 2.06 (1.66 to 2.55) ,0.0005
Anxiety symptoms per grade‡║ 1.98 (1.57 to 2.50) ,0.0005 2.20 (1.69 to 2.88) ,0.0005
Hepatitis C status‡¶
Negative 1
Positive 1.63 (0.89 to 2.97) 0.11
ART and VL status
VL ,50 on ART 1
Detectable on ART 1.81 (0.87 to 3.77)
Off ART 0.76 (0.34 to 1.68) 0.19
Current CD4 count per +100 cells/mm3 0.99 (0.91 to 1.09) 0.88
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completing higher education (aOR 1.89, 95% CI: 1.17 to
3.05); confounding (aOR 2.07, 95% CI: 1.31 to 3.27) or
contributing medical conditions (aOR 2.02, 95% CI: 1.22 to
3.36); ability to afford basic needs most of the time (aOR
1.91, 95% CI: 1.25 to 2.90), some of the time (aOR 3.56, 95%
CI: 1.86 to 6.82), or not at all (aOR 3.80, 95% CI: 1.85 to
7.81); being unable to work (aOR 4.68, 95% CI: 2.55 to 8.59)
or unemployed for other reasons (aOR 2.11, 95% CI: 1.41 to
3.14) compared with those in employment; depressive
symptoms (aOR 2.75 per grade on the PHQ-9, 95% CI:
2.28 to 3.32); anxiety symptoms (aOR 3.24 per grade on the
GAD-7, 95% CI: 2.58 to 4.07); and $10 years since HIV
diagnosis (aOR 1.82, 95% CI: 1.12 to 2.97).
Accuracy of the Questionnaires as Tests for
Cognitive Impairment
After excluding participants with incomplete data, the
IADLS had sensitivity 40%, speciﬁcity 78% when used as
a test for severe cognitive impairment (prevalence 30/356,
8.4%) with a cutoff of decline in $2 ADLs (Fig. 2). There
were 12 true positives, 253 true negatives, 73 false positives,
and 18 false negatives equating to positive LR 1.79, negative
LR 0.77, and DOR 2.31. The questionnaire had worse
sensitivity and better speciﬁcity when used with a cutoff of
a higher number of ADLs, and LRs and DORs were
consistently poor (close to 1).
The most balanced trade-off between sensitivity and
speciﬁcity on the MOS-HIV symptom scale was at a cutoff of
$7 points, giving sensitivity 48%, speciﬁcity 69% as a test
for severe cognitive impairment (prevalence 48/440, 10.9%).
There were 23 true positives, 271 true negatives, 121 false
positives, and 25 false negatives giving positive LR 1.55,
negative LR 0.75, and DOR 2.06. The questionnaire had
better accuracy overall at higher cutoffs at the expense of poor
sensitivity (high false-negative rates). At lower cutoffs in the
range of 2–5 points, sensitivity was improved at 50%–73%,
but speciﬁcity was markedly down at 27%–57%, and both
positive LR and DOR were consistently ,2.
Both questionnaires were, in general, less sensitive and
less speciﬁc when compared with a reference standard of mild
cognitive impairment. We conducted exploratory analyses
with exclusion of the most severely anxious or depressed
participants, and this made no improvement to the diagnostic
accuracy statistics for either outcome measure (IADLS or
MOS-HIV score).
DISCUSSION
In this study of HIV+ outpatients at 5 clinics in Europe,
80% reported cognitive symptoms in the past 4 weeks, and just
over 20% reported decline in their ADLs and attributed this to
cognitive impairment. There were associations between poorer
cognitive function (especially reaction time, speed, and
attention) and both self-reported decline in ADLs and increas-
ing frequency of cognitive symptoms. However, symptoms of
depression and anxiety, longer time since HIV diagnosis,
unemployment, and difﬁculty affording basic needs were also
strongly associated with cognition-related symptoms and
functional decline. In addition, lower educational attainment
and comorbid medical conditions were associated with cogni-
tive symptoms. All of our observed associations may have
multiple explanations, and causality could be in either direction
(particularly in the relationships between employment and
ﬁnancial means and the outcomes of interest). The accuracy of
both questionnaires, modeled as diagnostic tests for cognitive
impairment, was relatively poor and below a level likely to be
acceptable for individual patient use.
These results imply that patients who report symptoms
of cognitive impairment, or declining everyday function,
should be assessed for depression, anxiety, concomitant
medical conditions, and ﬁnancial difﬁculties. Failure to
recognize these important elements of patients’ lived experi-
ences risks diagnostic delay, failure to address important
TABLE 2. (Continued ) Factors Associated With Self-Reported Decline in ADL Attributed to Cognitive Impairment
Unadjusted OR (95% CI) P aOR (95% CI)* P
Nadir CD4 count per +100 cells/mm3 1.00 (0.91 to 1.09) 0.94
Time since HIV diagnosis
,5 yrs 1 1
5–10 yrs 4.09 (1.90 to 8.77) 3.18 (1.42 to 7.13)
$10 yrs 3.36 (1.64 to 6.90) 0.001 3.62 (1.62 to 8.09) 0.005
Previous AIDS
No 1
Non-CNS 0.93 (0.49 to 1.77)
CNS conditions 1.57 (0.40 to 6.22) 0.79
*Adjusted models include age, sex, education, ethnic group, and study site.
†Confounding and contributing medical conditions as deﬁned by the Frascati criteria3 and CHARTER cohort analysis.2
‡Excludes missing data.
§Deﬁned by the modiﬁed (2-question) AUDIT-C questionnaire: a positive score was $4 points for men or $3 points for women.
║Depression (PHQ-9) grades were as follows: 0–4, none/minimal; 5–9, mild; 10–14, moderate; 15–19, moderate-severe; 20–27, severe. Anxiety (GAD-7) grades were as follows:
0–4, none/minimal; 5–9, mild; 10–14, moderate; 15–21, severe.
¶Deﬁned as the most recent HCV RNA assay or the most recent antibody result in the absence an RNA result.
ART, antiretroviral therapy; CNS, central nervous system; MSM, men who have sex with men; VL, viral load.
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TABLE 3. Factors Associated With Frequency of Symptoms of Neurocognitive Impairment
Crude OR (95% CI) P aOR (95% CI)* P
Age per +10 yrs 0.96 (0.81 to 1.13) 0.59 0.93 (0.77 to 1.12) 0.43
Gender and sexual orientation
MSM 1 1
Other men 1.14 (0.72 to 1.81) 1.23 (0.69 to 2.19)
Women 1.12 (0.70 to 1.79) 0.79 1.75 (0.98 to 3.12) 0.16
Ethnic group
White 1 1
Other or not known 1.67 (1.00 to 2.77) 0.048 1.15 (0.65 to 2.02) 0.64
Education
University/higher 1 1
Secondary 1.22 (0.81 to 1.84) 1.25 (0.80 to 1.95)
Primary only 1.77 (1.12 to 2.80) 0.016 1.89 (1.17 to 3.05) 0.010
Employment status
In employment 1 1
Unable to work 5.60 (3.12 to 10.1) 4.68 (2.55 to 8.59)
Other 2.12 (1.47 to 3.08) ,0.0001 2.11 (1.41 to 3.14) ,0.0001
Site
London 1 1
Rome 0.47 (0.30 to 0.72) 0.38 (0.23 to 0.62)
Copenhagen 0.36 (0.20 to 0.65) 0.41 (0.23 to 0.76)
Minsk 0.54 (0.26 to 1.15) 0.0001 0.44 (0.18 to 1.10) 0.0002
Mean Z (all domains) per +1 SD 0.78 (0.65 to 0.92) 0.005 0.71 (0.58 to 0.87) 0.001
Speed Z per +1 SD 0.71 (0.62 to 0.82) ,0.0005 0.68 (0.58 to 0.80) ,0.0005
Attention/working memory Z per +1 SD 0.67 (0.54 to 0.84) ,0.0005 0.60 (0.47 to 0.77) ,0.0005
Executive function Z per +1 SD 0.99 (0.92 to 1.06) 0.73 0.99 (0.92 to 1.07) 0.86
Verbal memory Z per +1 SD 0.93 (0.84 to 1.03) 0.17 0.87 (0.77 to 0.98) 0.025
Verbal ﬂuency Z per +1 SD 0.85 (0.72 to 1.00) 0.043 0.84 (0.71 to 1.00) 0.044
Confounding comorbid condition†
No 1 1
Yes 2.30 (1.47 to 3.61) ,0.0005 2.07 (1.31 to 3.27) 0.002
Contributing comorbid condition†
No 1 1
Yes 1.80 (1.12 to 2.89) 0.016 2.02 (1.22 to 3.36) 0.006
Can afford basic needs‡
Always 1 1
Most of the time 1.98 (1.31 to 2.97) 1.91 (1.25 to 2.90)
Some of the time 3.69 (1.95 to 6.96) 3.56 (1.86 to 6.82)
No 4.25 (2.09 to 8.66) ,0.0001 3.80 (1.85 to 7.81) ,0.0001
Recreational psychoactive drugs in past 3 mo
No 1 1
Yes 1.43 (0.99 to 2.05) 0.054 1.16 (0.79 to 1.72) 0.47
Problem drinking‡§
No 1
Yes 1.16 (0.82 to 1.64) 0.69
Depressive symptoms per grade‡║ 2.92 (2.43 to 3.50) ,0.0005 2.75 (2.28 to 3.32) ,0.0005
Anxiety symptoms per grade‡║ 3.28 (2.63 to 4.07) ,0.0005 3.24 (2.58 to 4.07) ,0.0005
Hepatitis C status‡¶
Negative 1
Positive 1.18 (0.75 to 1.87) 0.47
ART and VL status
VL ,50 on ART 1
Detectable on ART 1.37 (0.71 to 2.64)
Off ART 0.93 (0.54 to 1.59) 0.61
Current CD4 count per +100 cells 0.97 (0.91 to 1.04) 0.36
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needs, unnecessary investigations, and further anxiety. This is
similar to the conclusions of a large cohort study of HIV-
negative older adults in Amsterdam: “when an older person
complains about his or her memory and does not show actual
cognitive impairment or cognitive decline, one should be
aware that these complaints might reﬂect psycho-affective or
health problems. Adequate intervention in these psycho-
affective or health problems may improve quality of life.”33
The relationships between cognitive impairment, low
mood, and functional decline are complex and multidirec-
tional. Secondary analyses suggested that the effects of mood
and cognition on everyday function were relatively indepen-
dent, although we cannot exclude other explanations. In our
recently published report of the same study population, we
showed that severe depressive symptoms were associated
with cognitive impairment, particularly on timed tests.11 A
controlled intervention to improve patients’ depression or
anxiety symptoms might tease out the effect of low of mood
on subjective and objective cognitive outcomes.
Limitations to CIPHER study methodology and Cogstate
in general have been discussed in earlier reports,11,25 but some
deserve further mention here. Notably, selection biases may
have arisen as a result of our opportunistic sampling strategy,
with patients choosing to participate in the study on the basis of
their own concerns and self-perceived cognitive symptoms.
Also, the largely computerized neuropsychological methods
did not provide as comprehensive an assessment as traditional
assessment conducted by a neuropsychologist. Importantly, the
lack of HIV-negative controls prevents us from determining
whether our ﬁndings are speciﬁc to PLWH. However, there is
a body of literature from the general population concluding that
psychological and psychiatric factors are as important as
cognitive function to subjective memory complaints. In their
conceptual framework for research into subjective cognitive
decline in preclinical Alzheimer disease, Jessen et al34 note that
mood- and anxiety-related symptomsmay be both a confounder
of the relationship between subjective cognitive decline and
subsequent dementia and an early symptom of dementia. An
analogous situation might be at work in HIV-related
cognitive impairment.
Despite initially positive results with a three-question
symptom tool1 and the MOS-HIV cognitive questions,35
TABLE 3. (Continued ) Factors Associated With Frequency of Symptoms of Neurocognitive Impairment
Crude OR (95% CI) P aOR (95% CI)* P
Nadir CD4 count per +100 cells 0.99 (0.93 to 1.06) 0.83
Time since HIV diagnosis
,5 yrs 1 1
5–10 yrs 1.45 (0.91 to 2.30) 1.26 (0.77 to 2.06)
$10 yrs 1.62 (1.08 to 2.43) 0.024 1.82 (1.12 to 2.97) 0.014
Previous AIDS
None 1
Non-CNS 1.36 (0.86 to 2.16)
CNS condition 2.28 (0.73 to 7.10) 0.17
*Adjusted models include age, sex, education, ethnic group, and study site.
†Confounding and contributing medical conditions as deﬁned by the Frascati criteria3 and CHARTER cohort analysis.2
‡Excludes missing data.
§Deﬁned by the modiﬁed (2-question) AUDIT-C questionnaire: a positive score was $4 points for men or $3 points for women.
║Depression (PHQ-9) grades were as follows: 0–4, none/minimal; 5–9, mild; 10–14, moderate; 15–19, moderate-severe; 20–27, severe. Anxiety (GAD-7) grades were as follows:
0–4, none/minimal; 5–9, mild; 10–14, moderate; 15–21, severe.
¶Deﬁned as the most recent HCV RNA assay or the most recent antibody result in the absence an RNA result.
ART, antiretroviral therapy; CNS, central nervous system; MSM, men who have sex with men; VL, viral load.
FIGURE 2. Receiver operator curves
showing sensitivity and specificity of
(left) number of ADL affected and
(right) symptom frequency score as
tests for mild (dashed line) or severe
(solid line) cognitive impairment.
The dotted diagonal line shows the
line of no diagnostic information.
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several studies have reported poor test accuracy of ADL and
cognitive symptom scales in HIV+ patients.7–10 In 290
PLWH over 50 years in Great Britain and Ireland and 97
seronegative controls, other patient-reported outcome meas-
ures, including depression, falls, sexual function, and general
health, correlated poorly with cognitive impairment.8 Thames
et al36 divided 107 HIV-positive patients into 4 groups, on the
basis of whether they were impaired or unimpaired, and
whether they were accurate or inaccurate in their self-
assessment of this. Notably, only 38% were accurate, 33%
were impaired but did not report a decline, and 25% reported
a decline but did not have cognitive impairment. In similar
studies, it was reported that only 3337 and 37%38 of patients
gave answers to symptom questions that concurred with their
objective cognitive test scores. In an analysis of CNS HIV
Anti-Retroviral Therapy Effects Research (CHARTER)
cohort patients (n = 277) in the United States, impaired
everyday function was associated with depression, unem-
ployment, ﬁndings on neuromedical examination, and
physician-assigned Karnofsky score. Although patients were
able to rate their own overall level of ability, they were poor
at correctly attributing their difﬁculties to cognitive versus
physical problems.7
Patients’ symptoms are important because they guide
clinical decisions, but clearly there are reasons other than
neurological disease why patients and study participants may
report symptoms. First, PLWH may have psychiatric problems,
excessive substance use, or some other reversible cause for their
symptoms. Second, depression or anxiety may cause them to
perceive a functional decline that is not present. Third, they may
be hypervigilant for symptoms or worried about normal everyday
experiences, although not having any psychiatric disorder.
Fourth, there may be desirability bias: they say what they think
the clinician or researcher wants to hear. Fifth, there may be
secondary gain as a result of misreporting their symptoms. And
sixth, the measuring instruments may lack construct validity and
fail to measure what they purport to measure.
Differentiation of asymptomatic from symptomatic
HAND relies solely on estimating daily function at ADL,
and most published research in this area relies predominantly
on participants’ self-report. There are limited data on more
accurate and reliable measures of everyday performance, such
as third-party observation or performance-based measures.12,13
This has crucial implications for the interpretation of longitu-
dinal studies in which the risk of change from ANI to MND is
measured, such as the United States CHARTER cohort,39 the
Canadian OHTN Cohort,6 and the French Aquitaine cohort.40
For example, in the Ottawa cohort, depression was a major risk
factor for change from ANI to MND.6 Because self-reported
functional impairment is associated with depression, change
from ANI to MND does not always indicate decline in
neurocognitive abilities. In addition, change from ANI to
MND in longitudinal studies should not be viewed as pro-
gressive, unidirectional deterioration (as is implied using
Kaplan–Meier plot analyses). The CHARTER cohort used
a more robust method of both self-reported and performance-
based assessments to discriminate ANI from MND.39 These
issues should be taken into consideration in the design and
analysis of future HAND cohort studies.
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